A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants

The New England Journal of Medicine
Lu-Ann PapileD K Stevenson

Abstract

Ventilator-dependent premature infants are often treated with dexamethasone. However, the optimal timing of therapy is unknown. We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator-dependent very-low-birth-weight infants (501 to 1500 g) who had respiratory index scores (mean airway pressure x the fraction of inspired oxygen) of 52.4 at two weeks of age. One hundred eighty-two infants received dexamethasone for two weeks followed by placebo for two weeks, and 189 infants received placebo for two weeks followed by either dexamethasone (those with a respiratory-index score of > or =2.4 on treatment day 14) or additional placebo for two weeks. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously or orally for five days, and the dose was then tapered. The median time to ventilator independence was 36 days in the dexamethasone-placebo group and 37 days in the placebo-dexamethasone group. The incidences of chronic lung disease (defined as the need for oxygen supplementation at 36 weeks' postconceptional age) were 66 percent and 67 percent, respectively. Dexamethasone was associated with an increased incidenc...Continue Reading

Associated Clinical Trials

References

Dec 27, 1979·The New England Journal of Medicine·D L Sackett, M Gent
Jan 1, 1990·Archives of Disease in Childhood·P C NgP R Dear
Jun 8, 1989·The New England Journal of Medicine·J J CummingsS J Gross
Dec 1, 1988·Controlled Clinical Trials·L J Wei, J M Lachin
Jan 1, 1987·Developmental Pharmacology and Therapeutics·M C MammelS J Boros
Jul 16, 1987·The New England Journal of Medicine·B Freedman
Jan 1, 1996·Archives of Disease in Childhood. Fetal and Neonatal Edition·E S ShinwellS Gottfried

❮ Previous
Next ❯

Citations

Mar 12, 2002·Pediatric Pulmonology·G MorietteP H Jarreau
Feb 13, 2001·Obstetrics and Gynecology·R L Goldenberg, L L Wright
Jun 23, 2000·Clinics in Perinatology·T M O'Shea, O Dammann
Mar 24, 1999·Early Human Development·M Hack, A A Fanaroff
Apr 2, 2003·Seminars in Neonatology : SN·David G Grier, Henry L Halliday
Feb 26, 2004·Paediatric Respiratory Reviews·Richard J Martin, Michele C Walsh
Feb 26, 2004·Paediatric Respiratory Reviews·Henry L Halliday
Apr 12, 2000·Journal of Paediatrics and Child Health·L Doyle, P Davis
May 31, 2001·Pediatrics International : Official Journal of the Japan Pediatric Society·M MizobuchiH Nakamura
Jan 11, 2001·The New England Journal of Medicine·A R StarkUNKNOWN National Institute of Child Health and Human Development Neonatal Research Network
Nov 9, 2007·The New England Journal of Medicine·David K Stevenson
Oct 11, 2005·Acta Paediatrica. Supplement·William W Hay
Apr 11, 2003·Clinical Obstetrics and Gynecology·Endla K Anday, Daniel Conway
Jun 3, 2000·Current Opinion in Pediatrics·J Gnanaratnem, N N Finer
Jan 27, 2004·The Pediatric Infectious Disease Journal·Thuy-Van P Tran, Leonard E Weisman
Apr 22, 1999·Archives of Disease in Childhood. Fetal and Neonatal Edition·T F FokK W So
Oct 21, 2000·Archives of Disease in Childhood. Fetal and Neonatal Edition·E S ShinwellE Gottfried
Jun 23, 2001·Archives of Disease in Childhood. Fetal and Neonatal Edition·T DebillonM Dehan
Mar 8, 2002·Archives of Disease in Childhood. Fetal and Neonatal Edition·D L ArmstrongJ E Harding
Jul 10, 1999·Pediatric Research·T RotschildR D Higgins
Apr 4, 2002·Drugs·Gideon KorenArne Ohlsson
Apr 1, 2014·Indian Journal of Pediatrics·Julie BartholomewApostolos Papageorgiou
Jun 28, 2006·Journal of Perinatology : Official Journal of the California Perinatal Association·W W Hay
Jun 29, 2000·Archives of Disease in Childhood. Fetal and Neonatal Edition·S K Sinha, S M Donn
Feb 22, 2012·Clinics in Perinatology·Kristi Watterberg
Sep 27, 2003·Seminars in Perinatology·Barbara J Stoll, Nellie Hansen
Jul 25, 2006·Seminars in Perinatology·Manoj A Biniwale, Richard A Ehrenkranz
Jan 12, 2001·Seminars in Perinatology·J P Kinsella, S H Abman
Jan 10, 2002·Seminars in Perinatology·A C Vidaeff, J M Mastrobattista
Jan 10, 2002·Seminars in Perinatology·K A Kennedy
Feb 26, 2000·Clinics in Perinatology·P J Thureen, W W Hay
Aug 10, 2002·Clinics in Perinatology·Sarah Jane Schwarzenberg, Andras Kovacs
Apr 26, 2002·Seminars in Neonatology : SN·T M O'Shea, L W Doyle
May 4, 2002·Seminars in Neonatology : SN·P J Thureen, W W Hay
Mar 8, 2014·Early Human Development·Marrit M HitzertArend F Bos
Dec 5, 2002·Seminars in Neonatology : SN·Sunil K Sinha, Steven M Donn

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.